Raj Chovatiya, MD, PhD, MSCI

Join Dermatology Times’ quarterly editor in chief Raj Chovatiya, MD, PhD, MSCI, as he reviews key updates in atopic dermatitis.

Fall Editor in Chief Raj Chovatiya, MD, PhD, MSCI, celebrates the joy of diverse traditions and reflects on the path to equity in dermatology as we move toward a brighter 2025.

You're allowed to be proud of yourself, no matter how long you have been in practice, writes our Fall Editor in Chief Raj Chovatiya, MD, PhD.

During an interview with Dermatology Times, Chovatiya outlined his Fall Clinical 2024 presentations on chronic hand eczema and early career controversies.

The conference will feature presentations on a number of disease states, therapeutic options, and new clinical data.

Dermatology offers the power of choice, and it can be exactly what you make of it, writes our Fall Editor in Chief Raj Chovatiya, MD, PhD.

Panelists offer concluding insights and emphasize the critical role of comparative studies in advancing atopic dermatitis treatment strategies.

Key opinion leaders examine upadacitinib's role in managing atopic dermatitis and its impact on improving patients' quality of life.

Dermatology experts provide critical analysis and interpretation of data from clinical trials to inform evidence-based practice in the field.

Dermatology experts analyze the superior outcomes of upadacitinib compared with dupilumab across key efficacy measures in atopic dermatitis treatment.

Medical experts examine the practical application of clinical study results to real-world atopic dermatitis management strategies.

Atopic dermatitis experts evaluate the integration of composite scores and quality of life measures as a new benchmark for comprehensive disease management.

Key opinion leaders in the management of dermatological disorders assess the effectiveness of systemic therapies in patients undergoing treatment.

Raj Chovatiya, MD, PhD, discusses how approved AD therapeutics currently address itch and whether any therapeutics will eventually have a remittive effect.

Raj Chovatiya, MD, PhD, focused on understanding JAK inhibitors, discussing their clinical use and safety profiles for effective patient communication.

Raj Chovatiya, MD, PhD, takes a deep dive in the challenges, solutions, and further research needed to treat seborrheic dermatitis.

Raj Chovatiya, MD, PhD, reviews the varying degrees of influence of skin barrier disruption, immune dysregulation, and Malassezia yeast in seborrheic dermatitis.

Chovatiya was a lead author of the latest seborrheic dermatitis and roflumilast foam review published in the Journal of Clinical and Aesthetic Dermatology.

Earn CME credit and learn how to optimize a multimodal treatment approach for hidradenitis suppurativa.

Raj Chovatiya, MD, PhD, dissects the nomenclature of atopic dermatitis and shares the importance of understanding other conditions under the eczema umbrella.

Raj Chovatiya, MD, PhD, gives an overview of what all clinicians need to know about the updated atopic dermatitis guidelines published by the American Academy of Dermatology including approaches with systemic therapies, which therapeutic modalities to prioritize, and patient considerations to guide decision-making.

Raj Chovatiya, MD, PhD, delves into the conditions that could be red, itchy, and not atopic dermatitis. He explains the importance of knowing characteristics for various inflammatory conditions.

Chovatiya acknowledged the common sentiment among residents who, despite dedicating significant time to studying and working during residency, may feel unprepared.

Raj Chovatiya, MD, PhD, and Adelaide A. Hebert, MD, FAAD, review the study results for the ADORING 1 and ADORING 2 trials, as well as share closing thoughts on the use of tapinarof in management of AD.

Raj Chovatiya, MD, PhD, and Adelaide A. Hebert, MD, FAAD, comment on the tolerability and low discontinuation rates of tapinarof for patients in AD clinical trials, as well as discuss the adverse events associated with the drug.

Adelaide A. Hebert, MD, FAAD, shares insight on the eczema area and severity index 75 (EASI75) results from the ADORING 1 and ADORING 2 clinical trials for use of tapinarof in AD.

Expert dermatologists review the validated investigator global assessment for AD (vIGA-AD) response in the ADORING 1 and ADORING 2 trials for tapinarof.

Raj Chovatiya, MD, PhD, and Adelaide A. Hebert, MD, FAAD, discuss the rapid itch reduction results found in the clinical trials for tapinarof in AD, as well as primary end points of the studies.

Expert dermatologists highlight the patient characteristics in the ADORING 1 and ADORING 2 trials, both focusing on tapinarof for the treatment of AD.

Raj Chovatiya, MD, PhD, and Adelaide A. Hebert, MD, FAAD, review clinical trial data for tapinarof cream, 1% in the treatment of AD.